https://www.selleckchem.com/products/sb297006.html
A. We present the protocol and rationale for selection of the measures included in SCD-GA. We also outline the methods to determine feasibility and subsequently to optimize the SCD-GA in preparation for a larger multicenter validation study of the SCD-GA. Treatment of MS often begins with low-efficacy injectable disease-modifying therapy (iDMT). To compare the effect of fingolimod 0.5 mg/day on clinical, MRI, patient-reported, and safety outcomes, in treatment-naïve and previously treated (≥1 iDMT) patients with early MS. EARLIMS was a
Like
Comment
Share
